Label-free proteomics identifies Calreticulin and GRP75/Mortalin as peripherally accessible protein biomarkers for spinal muscular atrophy
2013 · Genome Medicine · 37 citations
https://doi.org/10.1186/gm498
G
Gillian Hunter
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
38
Papers
643
Citations
12
h-index
12
i10-index
Gillian Hunter is an academic researcher from AstraZeneca (United Kingdom). The author has contributed to research in topics: Asthma and respiratory diseases & Pharmaceutical studies and practices & Neurogenetic and Muscular Disorders Research. The author has an h-index of 12, co-authored 33 publications.
ORCID: 0000-0002-1953-0058Papers by this author
worksEvaluation of Antibody Properties and Clinically Relevant Immunogenicity, Anaphylaxis, and Hypersensitivity Reactions in Two Phase III Trials of Tralokinumab in Severe, Uncontrolled Asthma
2019 · Drug Safety · 18 citations
https://doi.org/10.1007/s40264-018-00788-w
Efficacy of Biologics in Patients with Allergic Severe Asthma, Overall and by Blood Eosinophil Count: A Literature Review
2023 · Advances in Therapy · 15 citations
https://doi.org/10.1007/s12325-023-02647-2
Effect of Tezepelumab on Lung Function in Patients With Severe, Uncontrolled Asthma in the Phase 3 NAVIGATOR Study
2023 · Advances in Therapy · 13 citations
https://doi.org/10.1007/s12325-023-02659-y
Effect of tezepelumab on healthcare utilization in patients with severe, uncontrolled asthma
2023 · Annals of Allergy Asthma & Immunology · 8 citations
https://doi.org/10.1016/j.anai.2023.05.028
Efficacy of Tezepelumab in Adults With Severe, Uncontrolled Asthma Across Multiple Exacerbation Trigger Types: The Phase 3 Direction Study
2025 · American Journal of Respiratory and Critical Care Medicine · 0 citations
https://doi.org/10.1164/ajrccm.2025.211.abstracts.a5549
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat